The use of recombinant DNA methods to create vaccines against infectious agents is currently of great interest. Toxic proteins serve as major virulence determinants and hence as vaccine candidates against many bacterial diseases. For toxic proteins that are known to act by enzymatic mechanisms, a potential route to creating an immunogenic, nontoxic form (i.e., a toxoid) is to identify and mutate a crucial active-site residue. Here we report the successful application of this approach to create a toxoid of Pseudomonas aeruginosa exotoxin A (ETA).
P. aeruginosa is a common and often life-threatening pathogen of immunocompromised hosts (e.g., leukemia, intensive care, or burn patients) and cystic fibrosis patients (10, 24) . The organism produces several potential virulence factors, the most toxic of which is ETA, a 613-residue cytocidal protein. In experimental pseudomonas infections, passive immunization against ETA has been reported to confer significant protection to burned mice (20, 21) . In human infections, high serum antitoxin levels have been correlated with a greater chance of survival (5, 23 (3) , and site-directed mutagenesis experiments supported the notion that this residue plays a key role in catalysis. When Glu-553 was replaced by aspartic acid or cysteine, the enzymatic and cytotoxic activities of the protein were reduced by >103-and 104-fold, respectively (11, 18) .
In an effort to produce a virtually nonrevertible mutant of ETA that was devoid of ADP-ribosyltransferase activity and toxicity, we deleted the codon for Glu-553 by oligonucleotide-directed mutagenesis of the cloned ETA gene in Escherichia coli. A 491-base-pair BamHI-HindIII fragment of pCDPT2 (12) was mutagenized with a synthetic oligonucleotide (5'-CGAGAATGGTCAGGCGCCCGCC-3') in the M13mp8 system (27) . Deletion of Glu-553 was confirmed by DNA sequence analysis (25) after subcloning into the expression vector pCDptac2 (11 (E553A-ETA) was expressed in E. coli JM103 (11) and purified from crude bacterial sonic extracts to about 95% homogeneity by chromatography on phenyl-Sepharose, DEAE-Sephacel, and immunoaffinity columns (Fig. 1) . The purified protein comigrated with authentic ETA (Mr, 66,583) from P. aeruginosa PA103 on sodium dodecyl sulfate-polyacrylamide gels (Fig. 1) . No degradation products or loss from the main band were detected even after several months of storage.
To analyze the effects of the mutation, we measured immunoreactivity, cytotoxicity, and ADP-ribosyltransferase and NAD-glycohydrolase activities of purified E553A-ETA. Whereas immunoreactivity of the purified protein was identical to that of wild-type toxin (as measured by radioimmunoassay), all other activities of the mutant protein were undetectable, to the limits of sensitivity of our assays (Table  1) . NAD-glycohydrolase activity (representing a nonphysiological side reaction involving the hydrolysis of NAD to ADP-ribose, nicotinamide, and H+) was at least 103-fold lower than that of wild-type ETA. ADP-ribosyltransferase activity, assayed by incorporation of radiolabel from [32P]NAD into wheat germ EF-2, was at least 106-fold lower than that of wild-type ETA, and cytotoxicity, measured as inhibition of protein synthesis in mouse LM929 fibroblasts, was diminished by a similar factor. Preincubating fibroblasts with E553A-ETA efficiently protected them from the action of wild-type ETA, indicating that the mutant protein retained the capacity to bind and block cell surface receptors (Fig. 2) . The drastic reduction in cytotoxicity therefore correlates with loss of enzymatic activity. The concentrations of E553A-ETA needed for protection (about 103-fold excess over ETA) are in agreement with values previously reported (11). (12) . Ten picomolar ETA, without E553A-ETA, inhibited protein synthesis of the fibroblasts by 55% (defined as 0% protection).
In concordance with the in vitro toxicity results, E553A-ETA was also not toxic in vivo. Whereas the 50% lethal dose of authentic ETA was 0.158 ,ug (95% confidence interval, 0.073 to 0.344 ,g, determined by probit analysis), no mortality or toxic effects were seen within 30 days when mice were injected intraperitoneally with up to 100 ,ug of E553A-ETA. Administration of 100 ,ug of E553A-ETA to 4-week-old BALB/c mice caused no significant difference in weight gain compared with that of saline-injected controls. In contrast, 0.1 ,ug of ETA resulted in weight loss for 3 days, followed by decreased weight gains for 11 days. When mice were immunized with five doses of 1 ,g of E553A-ETA in complete Freund adjuvant, they produced high serum titers of specific antibodies as determined by enzyme-linked immunosorbent assay. The antibodies were protective in vitro and in vivo. They inhibited ADP-ribosyltransferase and cytotoxic activities of wild-type ETA (Fig. 3) , confirming the structural similarity between the wild-type and mutant proteins. Immunization of mice with 1 jig of E553A-ETA in complete Freund adjuvant raised the 50% lethal dose of ETA to 200 ,ug (95% confidence interval, 96 to 616 ,ug) from 0.2 ,ug in mice given adjuvant only (95% confidence interval, 0.1 to 0.4 ,ug). DISCUSSION The results suggest that the loss of toxicity of E553A-ETA is solely attributable to the absence of NAD:EF-2 ADPribosyltransferase activity. Consistent with this notion, receptor-binding activity, a property of domain I (1, 13, 15 (8, 9) have reported on the immunogenic and protective effects of P. aeruginosa 0 polysaccharide-ETA conjugates on human volunteers and in animal models of infection. Inclusion of other virulence factors in the formulation (e.g., pili [26] and exoenzyme S, elastase, and other proteases [14] ) might enhance efficacy. Finally, it may be possible to use the current approach to generate immunogenic, nontoxic forms of other toxins. Specifically, it is possible that toxins that catalyze ADPribosylation of other proteinaceous substrates besides EF-2 (e.g., pertussis toxin and cholera toxin) are evolutionarily related to the EF-2-specific toxins. These toxins may therefore contain acidic residues that are crucial for catalysis and which might be identified by photolabeling and deleted or replaced without causing major structural perturbations. The experiments described here provide a logical precedent for this approach.
